Company intelligence / Profile preview
Zhejiang Vimgreen Pharmaceuticals
Hangzhou, Zhejiang Province, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Vimgreen Pharmaceuticals has advanced at least one small molecule drug candidate to Phase 2 clinical trials, with a focus on A2A receptor antagonists. The company also engages in early-stage discovery, such as novel PI3Kdelta inhibitors for oncology applications. Recent patents indicate ongoing innovation in triazolotriazine scaffolds targeting the adenosine pathway.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Zhejiang Vimgreen Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Vimgreen Pharmaceuticals.